A Japanese family with a novel nonsense mutation in the TITF-1 gene (p.Y98X) is described.
Introduction
Benign hereditary chorea (BHC) (MIM 118700) is a rare autosomal dominant choreic disorder with onset in childhood [1] [2] [3] [4] [5] . In contrast to Huntington disease, choreic movement in BHC is recognized as non-progressive and patients have normal or slightly below normal intelligence.
Choreic movements tend to be attenuated in adolescence or early adulthood in some families [6] . In addition to chorea, some patients exhibit other neurological features, such as dystonia, myoclonic jerks, intentional tremor, dysarthria, and gait disturbance [7] .
Recently, mutations in the gene encoding thyroid transcription factor-1, TITF-1, a member of the NK2 gene family, have been identified in BHC pedigrees [3] . TITF-1 is a homeodomain-containing transcription factor essential for organogenesis of the lung, thyroid, and basal ganglia. Since the discovery of TITF-1 gene mutations in this disorder, the clinical presentation and the phenotype have expanded with variable combinations of lung, thyroid, and neurological abnormalities [3, 4] .
Willemsen et al. [8] recently introduced the term "Brain-Thyroid-Lung syndrome" (MIM 610978) to emphasize the widespread involvement of multiple organ systems that can be present with TITF-1 mutations. At present, Brain-Thyroid-Lung syndrome is recognized as an allelic disorder of BHC with a more severe phenotype.
Here, we report a Japanese family with a novel nonsense mutation in the TITF-1 gene (p.Y98X).
The clinical phenotype of the proband was Brain-Thyroid-Lung syndrome, whereas those of her brother and mother were mild BHC with congenital hypothyroidism.
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Case report

Patient 1
The proband (patient 1, III-4), a 19-year-old Japanese girl, was the second child of non-consanguineous parents (Fig. 1A) . She was born at term after a normal pregnancy and presented with an elevated thyroid stimulating hormone (TSH) level detected by neonatal screening. At the age of 12 months, she developed pneumonia. Thyroid function was compensated at the age of 18 months, with an elevated TSH level of 28.77 μIU/mL (normal range: 0.2 -4.0), and a normal free T4 
Patient 2
Patient 2 (III-3) was the older brother of patient 1. He was born at term without signs of respiratory distress. Mild congenital hypothyroidism was detected at neonatal screening (TSH 12.6 μIU/mL, fT4 1.14 ng/dL) and levothyroxine replacement therapy was started at 6 months of age. His motor development was markedly delayed with standing up at 30 months, whereas his mental development was compatible with normal milestones. He developed mild choreic movement at 6 years old, which gradually disappeared in adolescence. Brain MRI examined at 5 years old showed no abnormal findings. He graduated from a regular community high school and began working as a BHC with a novel TITF-1 mutation 6 child-minder.
Patient 3
Patient 3 (II-4) was the mother of patient 1 and 2. She also showed motor developmental delay and developed mild choreic movement of the extremities at around 6 years old. Her involuntary movements gradually disappeared in adolescence. She graduated from a regular community high school and worked as a sales clerk at a supermarket. Although her thyroid function was not analyzed in childhood, blood test performed at 47 years old showed elevated TSH level of 13.2 μIU/mL, and normal fT4 level of 0.85 ng/dL (normal range: 1.0 -2.0) and fT3 level of 2.84 pg/mL (normal range:
2.3 -4.0). Neurological examination of the patient performed at 47 years old showed no abnormal findings, including involuntary movement, muscle atrophy, and weakness. She had no history of episodes of pulmonary disease (Table 1) .
DNA analysis
As clinical findings in this family were suggestive of BHC/Brain-Thyroid-Lung syndrome, genetic analysis for this disorder was performed with informed consent. DNA was extracted from peripheral leukocytes of patient 1 (III-4) and patient 3 (II-4) according to the standard protocol. All 3 exons of the TITF-1 gene were amplified by polymerase chain reaction (PCR) as described previously. [9] Direct sequence analysis of the PCR-amplified DNA revealed that both patients were heterozygous for C to G substitution at position 294 of the coding sequence (c.294C>G) in exon 1 (Fig. 1B) . This 7 mutation is predicted to lead to a premature stop at codon 98 (p.Y98X), and is located before the homeodomain of TITF-1. Huntington disease was excluded by genetic testing.
Discussion
We reported a Japanese family with BHC/Brain-Thyroid-Lung syndrome confirmed to possess a novel heterozygous mutation (p.Y98X) in the TITF-1 gene. (Table 1) [12, 13, [19] [20] [21] [22] 24] , indicating that BHC and Brain-Thyroid-Lung syndrome are not entirely distinct but represent extreme points on a spectrum [28] . Intrafamilial phenotypic variation in this disorder may be explained by differences in modifier genes that produce a different genetic background in the same family. Indeed, the activity of TITF-1 is highly dependent on its interactions with other transcription factors and coactivators, including GATA-6, NF-1, RAR, CBP/p300, SRC-1, and TAZ [29] [30] [31] [32] [33] [34] . In addition, deficient transcriptional activity of mutant TITF-1 (p.P202L) was completely rescued by cotransfection of wild-type PAX8 in HEK293 cells [13] .
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Environmental factors could also modify the disease phenotype, as monozygotic twins with a TITF-1 mutation showed different phenotypes [13] .
Although choreic movement in BHC/Brain-Thyroid-Lung syndrome is recognized as non-progressive, the proband (patient 1) showed re-exacerbation of choreic movement at puberty.
Similar re-exacerbation was observed in two other patients [21, 24] . Glik et al. [24] reported a BHC patient with p.S145X mutation who showed mild worsening of chorea at the age of 30. Salvatore et al. [21] also reported a BHC patient with p.S217X mutation who showed worsening of choreic movement during puerperium at the age of 19. In terms of treatment for BHC, there have been two reports [14, 22] in which high doses of levodopa significantly improved gait and choreic movements.
Although levodopa did not improve choreic movement, dopamine agonist was effective in patient 1,
suggesting that levodopa and/or dopamine agonists may compensate for underdeveloped dopaminergic pathways in this disorder [14] . The results of brain MRI in our patients appeared normal; however, several abnormal findings, including ventricular dilatation, cystic mass in the posterior part of the sella, empty sella, and dysgenesis of the pallidum, have been reported in some patients with TITF-1 mutation. Furthermore, advanced MRI analysis showed metabolic and volumetric abnormalities of the basal nuclei in this disorder [35] . Despite recent progress in molecular genetics of BHC/Brain-Thyroid-Lung syndrome, the pathophysiological mechanism of this disorder remains to be elucidated. 
